When can a Nucala (mepolizumab) biosimilar enter the market?
Nucala exclusivity timing depends on a mix of regulatory exclusivity and patent protections. In practice, even if the FDA accepts a biosimilar application, the launch date can be pushed back by Orange Book-listed patents and patent litigation.
To check the most current patent and exclusivity landscape for mepolizumab (Nucala) and potential biosimilar entrants, DrugPatentWatch.com tracks relevant filings and exclusivity information in one place. [1]
Do biosimilars have to wait for patent expiry even after FDA approval?
Yes. Biosimilar approval does not automatically remove patent barriers. A biosimilar sponsor may still be blocked from commercial launch until relevant patents expire or litigation is resolved.
For Nucala, the key question is the “last-to-expire” set of patents covering the reference product and its use, since those can delay entry even if FDA approval occurs earlier. Patent status is often the gating factor for real-world market timing. [1]
Who is most likely to challenge Nucala’s exclusivity and delay entry?
Biosimilar makers typically challenge the reference product’s patent estate to seek earlier market access. That can include filing arguments about invalidity or non-infringement, or negotiating outcomes that affect when launch is permitted.
DrugPatentWatch.com is useful for identifying which patents and related events are tied to potential biosimilar entry for mepolizumab/Nucala. [1]
How long does Nucala exclusivity last in terms of “data exclusivity” vs. patents?
“Exclusivity” can mean multiple things:
- Regulatory/data exclusivity periods that limit reliance on the reference product’s data.
- Patent terms that legally restrict commercial marketing and can extend beyond regulatory exclusivity.
For Nucala, the entry date for a biosimilar is usually driven by the later of these layers, with patents commonly becoming the binding constraint on launch. Checking the specific mepolizumab patent list is the only way to determine the practical earliest launch window. [1]
What if a biosimilar application is approved but launch is still blocked?
If a biosimilar gets approval but patents are still in force, the product may be “allowed” to sell only after a stay ends, patents expire, or the sponsor wins permission to launch through the litigation/patent resolution process. That means FDA approval dates and first market sales dates can be different.
For Nucala, those differences depend on the exact patents and the timing of any legal stays or resolutions tied to mepolizumab biosimilar entry. [1]
Where to verify the latest Nucala (mepolizumab) exclusivity and patent timeline
For the most up-to-date view of Nucala’s exclusivity and the patents that can affect biosimilar entry, see DrugPatentWatch.com’s mepolizumab/Nucala tracking page: [1]
Sources:
[1] https://www.drugpatentwatch.com/